SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Hengrui Medicine

Status and phase: Terminated; Phase 1

Conditions: ER+ HER2- Advanced Breast Cancer

Treatments: Drug: SHR9549

Study type: Interventional

Funder types: Industry

Identifiers

NCT03596658

SHR9549-I-101

Details and patient eligibility

About

This is a phase 1 open label multicentre study of SHR9549 administered orally in patients with advanced estrogen receptor (ER) positive human epidermal receptor 2 (HER2) negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose(MTD). In addition, expansion cohort(s) at potential therapeutic dose(s) in patients will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of SHR9549.

Full description

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of SHR9549 in Women with Estrogen Receptor (ER) Positive Human Epidermal Receptor (HER-2) Negative Advanced Breast Cancer

Enrollment: 4 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18-70 years.
• Confirmation of ER positive; HER2 negative Advanced breast cancer
• Documented disease progression after at least 6 months prior endocrine therapy for ER positive breast cancer.
• Receipt of ≤2 lines of prior chemotherapy for advanced disease.
• Any menopausal status.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and with minimum life expectancy of 12 weeks.

Exclusion criteria

• Any anti-cancer drugs for the treatment of advanced breast cancer within 14 days of the first dose of study treatment.
• Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia.
• Patient who is unsuitable for endocrine therapy alone including presence of life-threatening metastatic visceral disease.
• uncontrolled central nervous system metastatic disease.
• Any evidence of severe or uncontrolled systemic diseases.
• Inadequate bone marrow reserve or organ function.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

SHR9549 dose escalation and expansion(s)

Experimental group

Description:

Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients

Treatment:

Drug: SHR9549